icon- folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
March 4-7, 2019
 		Back grey_arrow_rt.gif
 
 
 
Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591
 
 
  Yesterday the FDA approved the 1st 2-dug regimen of Dolutegravir+3TC: once-daily, single-tablet regimen
https://www.viivhealthcare.com/en-us/us-news/us-articles/2019/us-fda-approves-viiv-healthcares-dovato-dolutegravir-lamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naive-hiv-1-adults/
 
Dovato FDA Approval Press Release FINAL 4 8 19 PDF - (03/18/19)
 
CROI: New HIV/ART Drugs at CROI 2019 - (03/18/19)
 
Full NATAP coverage:
Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
March 4-7, 2019
 
CROI: FAVOURABLE OUTCOME of IN VITRO SELECTIONS WITH NOVEL NRTI PRODRUG GS-9131 - (03/14/19)
 
CROI: 26th Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA - Eric S. Daar, M.D. - (03/29/19)
 
Hepatitis at CROI 2019: HCV, NASH, HBV; HIV+ MSM Reinfection in NYC; New HCV Cases Sharp Drop in London - (03/27/19)
 
Aging At CROI 2019 - (04/02/19)
 
I Keep Forgetting HIV, Aging, and Cognitive Disorders - plenary, Victor Vacour MD (03/29/19)
 
Delayed HCC Diagnosis in HIV/HCV Coinfected: HIV not linked to worse liver cancer survival in people with HCV - (03/26/19)
 
Suicide rates among adults living with HIV, 2000-2015 - (03/28/19)
 
CROI: Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)
 
CROI: Rebound Of HIV-1 In Cerebrospinal Fluid (CSF) After Treatment Interruption (TI) - (03/14/19)
 
 Bictegravir
 
 A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 96 - (10/05/18)
 
Phase III Randomized, Controlled Clinical Trial of Bictegravir Coformulated with FTC/TAF in a Fixed-dose Combination (B/F/TAF) versus Dolutegravir (DTG) + F/TAF in Treatment-naïve HIV-1 Positive Adults: Week 96 - (11/01/18)
 
BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS - (03/15/19)
 
Susceptibility to Bictegravir in Highly ARV Experienced Patients After INSTI Failure - (03/15/19)
 
High Level of Preexisting NRTI Resistance Prior to Switching to B/F/TAF: Study 4030 - (03/15/19)
 
CROI: Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance - (04/08/19)
 
BICTEGRAVIR CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF of HIV-INFECTED PATIENTS - (03/14/19)
 
 Doravirine
 
 Safety and Efficacy of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1 Infected Adults With Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations - (11/02/18)
 
CROI/2017: Doravirine in Non-Inferior To Darunavir+Ritonavir in Phase 3 Treatment-Naive Trial at Week 48 - (02/16/17) Lipids
 
Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591 (07/30/18)
 
CROI/2016: NNRTI-resistant Mutants Are Suppressed by Doravirine at Clinically Relevant Concentrations - (03/28/16)
 
CROI/2017: Multiple-Dose Treatment With Ritonavir Increases the Exposure of Doravirine - (03/29/17)
 
Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients (10/12/18)
 
 Dolutegravir + 3TC 2 drug Regimen
 
 Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG + 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG + TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: Subgroup Analyses in the GEMINI Studies - (11/05/18)
 
Efficacy of the Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+3TC) vs Dolutegravir Plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at W48 in Antiretroviral Naive Women: GEMINI Studies Subgroup Analysis (03/08/19)
 
Viral Decay Similar With 2- and 3-Drug Dolutegravir Regimens - - (10/30/18)
 
No Uptick in HIV Replication After Switch to DTG/3TC in Randomized Trial - - (10/29/18)
 
 Cabotegravir + Rilpivirine Long Acting
 
 Safety, Efficacy and Durability of Long-acting Cabotegravir (CAB) and Rilpivirine (RPV) as Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results - (11/05/18)
 
Comparison of Viral Replication Below 50 c/mL for Two-Drug (DTG + RPV) Versus Three-Drug Current Antiretroviral Regimen (CAR) Therapy in the SWORD-1 and SWORD-2 Studies - (11/05/18)
 
Durable Suppression 2 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies (07/27/18) resistance in failures; lipids; bone and renal bomarders
 
Comparison of HIV-1 Intermittent Viremia for Two Drug (DTG+RPV) vs Three Drug Current Antiretroviral Therapy in the SWORD-1 and SWORD-2 Studies - (11/02/18)
 
Safety and Efficacy of DTG+RPV in the Phase III SWORD-1 and SWORD-2 Studies: 48 Week Subgroup Analysis by Baseline Third Agent Class and Geographic Location - EACS 2017
 
Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - (11/05/18)
 
Adherence to Long-Acting CAB and RPV Injections Through 96 Weeks of Maintenance Therapy in LATTE-2 / Good adherence to injected cabotegravir and rilpivirine in 230 LATTE-2 participants - (07/31/18)
 
Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - oral talk has extra data - (11/02/18)
 
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 100 Results From the SWORD-1 and SWORD-2 Studies - (11/05/18)
 
Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG + 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG + TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: Subgroup Analyses in the GEMINI Studies - (11/05/18)
 
Comparison of Viral Replication Below 50 c/mL for Two-Drug (DTG + RPV) Versus Three-Drug Current Antiretroviral Regimen (CAR) Therapy in the SWORD-1 and SWORD-2 Studies - (11/05/18)
 
 MK-8591 & Fostemsavir
 
 Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates - (10/30/18)
 
Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 48 Subgroup Analysis in Randomised Cohort Participants - (11/05/18)
 
Pharmacokinetics of MK-8591, Dolutegravir and Tenofovir Disoproxil Fumarate Are Not Altered After Coadministration When Compared to Single Agent Administration- (11/09/18)